NCT03893669View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

November 30, 2012

Conditions

Prevention of Influenza

Interventions

BIOLOGICAL

NBP607

1 dose, 0.5ml, Intramuscular (IM) injection

BIOLOGICAL

Agrippal

1 dose, 0.5ml, Intramuscular (IM) injection

Trial Locations (1)

153-703

Korea University Guro Hospital, Seoul

All Listed Sponsors

lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT03893669 - Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter